Note: [01 Mar 2017] – The following is a consolidation of 13-501F1. It incorporates amendments to this document that came into effect on March 1, 2017. This consolidation is provided for your convenience and should not be relied on as authoritative.

FORM 13-501F1 CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS – PARTICIPATION FEE

MANAGEMENT CERTIFICATION

I, Richard Goldstein, an officer of Form 13-501F1 (the Form) being submicertify that to my knowledge, having extitle Form is complete and accurate.	itted hereunder to the Alber	ta Securities Commission and	
"signed" Name: Richard Goldstein Title: CFO	September 30, 2019 Date:		
Reporting Issuer Name:	Canntab Therapeutics Lin	nited_	
End date of previous financial year:	May 31, 2019		
Type of Reporting Issuer:	[] Class 1 reporting issuer	[] Class 3B reporting issuer	
Highest Trading Marketplace:	The CSE		
Market value of listed or quoted equite Equity Symbol	<u>v securities</u> :		
1st Specified Trading Period (dd/mm/		to	
Closing price of the security in the class last trading day of the specified trading such security was listed or quoted on the marketplace	period in which	\$ (i)	

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period	f	(ii)	
Market value of class or series	(i) x (ii)	\$(A)	
2nd Specified Trading Period (dd/mm/yy)			_ to
Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace	l	\$ (iii)	
Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period	f	(iv)	
Market value of class or series	(iii) x (iv)	\$ (B)	
3rd Specified Trading Period (dd/mm/yy)			_ to
Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace			
Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period	f	(vi)	
Market value of class or series	(v) x (vi)	\$ (C)	

4th Specified Trading Period (dd/mm/yy)	to		
Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace	\$(vii)		
Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period	(viii)		
(vii) x (viii) Market value of class or series	\$(D)		
5th Specified Trading Period (dd/mm/yy)	to		
Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace	\$		
Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period	(x)		
	\$(E)		
Average Market Value of Class or Series (Calculate the simple average of the market value of the class or series of security for each applicable specified trading period (i.e. A through E above))	\$		

(Repeat the above calculation for each other class or series of equity securities of the reporting issuer (and a subsidiary, if applicable) that was listed or quoted on a marketplace at the end of the previous financial year)

	Fair	value	of	outstan	ding	debt	securities:
--	------	-------	----	---------	------	------	-------------

Capitalization for the previous financial year (1) + (2) \$_____

Participation Fee \$_____

Late Fee, if applicable \$_____

Total Fee Payable \$_____

(Participation Fee plus Late Fee)